Genzyme Corporation has announced the plan to construct a major new Research & Development centre in Beijing, China.
The new facility will be located in Zhongguancun (ZGC) Life Science Park, an area dedicated to academic and government research centres as well as pharmaceutical and biotechnology companies.
The estimated cost for the construction of the 200,000 square-foot project is estimated to be around US$ 90 million.
The new facility will be used for R&D activities involving many of Genzyme’s main areas of focus like orthopaedics, transplant and immune disease, oncology, endocrinology and cardiovascular disease. It will also feature laboratory-scale operations for the Matrix-induced Autologous Chondrocyte Implantation, or the MACI® cell therapy and polyclonal antibody operations.
The facility is planned to be built on a green design in order to create a healthy and comfortable environment for the employees. It will feature low-impact environmental techniques and methods.
Genzyme is currently due to take the governmental authorisations for the facility and expects it to be functional from 2010.
